European Union: Infringement Of Second Medical Use Claims In Europe

It is possible to obtain a patent from the European Patent Office (EPO) based on a new medical use of a known drug. The claim can be directed to using the drug to treat a different disease, or using the drug in a new method of treatment, such as a new route of administration or a new dosage. The EPO has well-established requirements for the patentability of these so-called "second medical use" claims, but it does not consider issues of patent infringement. Infringement in Europe is currently assessed on a country-by-country basis by individual national courts.

Although these second medical use claims have been available in Europe since the 1980s, until recently it has been unclear how the manufacture and sale of a drug for a patented use can be distinguished in practice from the manufacture and sale of the same drug for a non-patented use. The English Court of Appeal has now clarified how infringement of such second medical use claims should be assessed in the United Kingdom.1

The Pregabalin Case in the United Kingdom

As discussed in our earlier article,2 Warner-Lambert has been involved in litigation across Europe relating to a second medical use patent granted by the EPO, directed to the use of pregabalin in the manufacture of a medicament for treating pain.

Pregabalin is approved for use in the United Kingdom in the treatment of general anxiety disorder (GAD), epilepsy, and neuropathic pain. Actavis was sued for infringement by Warner-Lambert after it applied for approval to sell pregabalin in the UK under a "skinny label" that referred only to the treatment of GAD and epilepsy, not covered by Warner-Lambert's patent. Warner-Lambert argued that the Actavis product would inevitably be used by physicians and prescribed by pharmacists for the treatment of pain, even though that treatment was not specifically mentioned on the product packaging.

The Court of Appeal concluded that Warner-Lambert's patent was invalid, and so there was no requirement to consider infringement. However, it took the opportunity to clarify the test that should be applied when considering infringement in this situation. The Court acknowledged that it is not straightforward to find a suitable balance between the needs of the parties: "The law is struggling on the one hand to give the patentee a proper reward for his contribution to the art by elucidating the new use for the drug, whilst at the same time not excluding the competing manufacturer from making and marketing the drug for its known purpose."

A key issue was whether a second medical use claim will only be infringed when it can be shown that the manufacturer specifically intends for its product to be used to treat the patented indication. The Court reviewed decisions from a number of other European courts that considered this issue, but found a variety of different approaches. In some cases, only the uses stated on the product packaging were taken into account, others looked at whether there was some element of encouragement by the manufacturer, and others considered whether steps had been taken by the manufacturer to prevent use for the patented indication.

The Court concluded that the question to be considered was whether Actavis knew, or could foresee, that at least some of the prescriptions written generically for pregabalin to treat pain would be fulfilled with its drug. The Court recognised an obligation on a manufacturer to take active steps if it is to enter a market where it stands to benefit from the patentee's patented invention. In order to avoid infringement, the manufacturer must show that it has taken all reasonable steps in its power to prevent its drug from being used in accordance with the patent.

What Must Be Done To Avoid Infringing Uses?

The approach proposed by the UK Court is consistent with the findings in related French proceedings,3 which assessed what another manufacturer, Sandoz, had done to prevent use of its pregabalin product for the patented indication in France. Sandoz had sent an information email to doctors and pharmacists prior to launch, stating that its product was not indicated for neuropathic pain. Sandoz had also agreed to send more explicit messages to physicians and pharmacists to describe how to prescribe or dispense its drug, in order to avoid infringement. Although Sandoz had a larger share of the market than was represented by non-pain use, the French court concluded that Sandoz had done enough to avoid direct infringement of Warner-Lambert's patent.

It is not clear from the UK decision what steps a manufacturer might need to take in the UK to establish that it did not intend for its product to be used for a patented indication. There is clearly a burden on the manufacturer to try to limit the use of its product to the non-patented uses. However, the Court's test does suggest that factors that are outside the control of the manufacturer, such as those based on the structure and processes of the healthcare system, will not be held against it.

In view of the flexibility that is afforded to individual doctors and pharmacists in the UK, it is unlikely that the efforts required by this test will be able to completely prevent the off-label use of generic products for patented uses. In some cases, patentees may need to consider taking further action themselves to enforce the prescription of only their approved drug for the patented use. For example, Pfizer has successfully obtained an injunction in the UK against NHS England (which oversees the operations of the English National Health Service), requiring them to instruct doctors to prescribe pregabalin only by the Pfizer brand name Lyrica when it is for use in treating pain.4

Despite the inability to completely prevent physicians and pharmacists from prescribing a generic drug for a patented indication, it is clear from this decision that a second medical use patent can be valuable. It can impose a burden on other manufacturers to try to prevent their products being used in accordance with the patent. A patent filing strategy involving follow-up patent applications directed to specific uses of a drug can therefore limit, or at least disrupt, the market for third party products, even after the basic patent protection for the product itself has expired.


1. Warner-Lambert Company LLC v Generics (UK) Ltd

. (t/a Mylan) & Ors [2016] EWCA Civ 1006 (13 October 2016)

2. Infringement of Second Medical Use Claims in the United Kingdom - Full Disclosure Patent Newsletter, November 2015

3. Warner-Lambert Company & Pfizer v. Sandoz, order of the presiding judge of the Tribunal de Grande Instance de Paris of 26 October 2015, Docket № 15/58725

4Warner-Lambert Co. v. Actavis Grp. Ptc EHF [2015] EWHC 485 (Pat).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
23 Sep 2018, Seminar, Chicago, United States

Finnegan is a sponsor of the Intellectual Property Owners Association Annual Meeting, supporting the Women in IP Networking Brunch.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions